Merck Institute for Science Education-ko ikertzaileekin lankidetzan egindako argitalpenak (6)

2022

  1. Pain and health-related quality of life with olaparib versus physician's choice of next-generation hormonal drug in patients with metastatic castration-resistant prostate cancer with homologous recombination repair gene alterations (PROfound): an open-label, randomised, phase 3 trial

    The Lancet Oncology, Vol. 23, Núm. 3, pp. 393-405

  2. Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study

    The Lancet Oncology, Vol. 23, Núm. 5, pp. 659-670

2020

  1. Pembrolizumab in microsatellite-instability-high advanced colorectal cancer

    New England Journal of Medicine, Vol. 383, Núm. 23, pp. 2207-2218

2017

  1. Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection

    New England Journal of Medicine, Vol. 376, Núm. 4, pp. 305-317

2011

  1. Boceprevir for untreated chronic HCV genotype 1 infection

    New England Journal of Medicine, Vol. 364, Núm. 13, pp. 1195-1206

2002

  1. Outcomes at 6 months for the direct comparison of tirofiban and abciximab during percutaneous coronary revascularisation with stent placement: The TARGET follow-up study

    Lancet, Vol. 360, Núm. 9330, pp. 355-360